CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2+ Breast Cancer

Publication date: 14 March 2016
Source:Cancer Cell, Volume 29, Issue 3
Author(s): Marcos Malumbres
CDK4/6 inhibitors have received approval for treating hormone-positive breast tumors, but whether other aggressive cancers respond to these molecules is not yet clear. In this issue of Cancer Cell, Goel et al. (2016) report an unexpected activity of CDK4/6 inhibitors in reducing mTOR function and re-sensitizing HER2-positive cancers to EGFR/HER2 blockade.

Teaser

CDK4/6 inhibitors have received approval for treating hormone-positive breast tumors, but whether other aggressive cancers respond to these molecules is not yet clear. In this issue of Cancer Cell, Goel et al. (2016) report an unexpected activity of CDK4/6 inhibitors in reducing mTOR function and re-sensitizing HER2-positive cancers to EGFR/HER2 blockade.


from Cancer via ola Kala on Inoreader http://ift.tt/1pHvz2L
via IFTTT